CCP
TEVA icon

Clough Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Clough Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,600
Closed -$353K – 237
2016
Q1 		$353K Buy
+6,600
New +$387K 0.02% 180
2014
Q2 		– Sell
-340,100
Closed -$18M – 220
2014
Q1 		$18M Buy
+340,100
New +$15.7M 0.56% 70

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Clough Capital Partners's TEVA Position: Q2 2016 in Review

Clough Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 6,600 shares — an estimated $353K sold.

Clough Capital Partners first reported a position in TEVA in Q1 2014 and held it in 2 quarters. The position peaked at $18M in Q1 2014. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

  • Clough Capital Partners reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Clough Capital Partners sold 6,600 Teva Pharmaceuticals shares in Q2 2016, an estimated $353K.
  • Clough Capital Partners first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Clough Capital Partners's Teva Pharmaceuticals position peaked at $18M in Q1 2014.
  • 812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Clough Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.